Ensovibep

DB19078InvestigationalProtein Based Therapies

Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19).

Mechanism
Curator reviewed
Also known as
Designed ankyrin repeat protein (synthetic bivalent human albumin-binding) fusion protein with designed ankyrin repeat protein (synthetic trivalent severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor binding domain-binding)
Code names
MP-0420

Resolves to

Compound
UNIIPV6AA88RDUCAS2451126-06-8
Targets
P0DTC2S

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ensovibep, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In